Clinical trials: Fatty Liver, Alcoholic
Non-Alcoholic Fatty Liver Disease
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Over the past 30 years, the prevalence of childhood obesity in the United States has tripled from 5% to 15%. Major consequences of obesity include insulin resistance, type- 2 diabetes, cardiovascular disease and nonalcoholic…
- Trial name
- NCT01285362
- Testing
- Fish Oil Supplementation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Omics-based Predictors of NAFLD/Potential NASH
The cascade of care for the non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) requires crossing the barriers for their diagnosis and treatment.
- Trial name
- NCT05301231
- Testing
- Genomics (DNA Extraction), Epi-genomics, Proteomics (Glycoproteomics)
- Where
- Egypt
- Volunteers
- 450 people
- Sponsor
- National Research Centre, Egypt
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Soluble Fibre Supplementation in NAFLD
The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Hepatic Steatosis
- Trial name
- FIND (NCT05480696)
- Testing
- Fructo-oligosaccharide enriched inulin supplement, Maltodextrin
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- McMaster University
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Non-Alcoholic Fatty Liver Disease
Gemcabene for the Treatment of Pediatric NAFLD
This is a multicenter, prospective, open-label, Phase 2, proof of concept study to test preliminary efficacy and safety of gemcabene in children with established nonalcoholic fatty liver disease (NAFLD) incompletely treated by…
- Trial name
- NCT03436420
- Testing
- Gemcabene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
NAFLD
Hydroxytyrosol and Vitamin E in Pediatric NASH
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Trial name
- NCT02842567
- Testing
- Hydroxytyrosol plus Vitamin E
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Inflammation, Fibrosis
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. We aim to determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLD.
- Conditions
- Inflammation, Fibrosis, Insulin Resistance
- Trial name
- VITENAFLD (NCT00655018)
- Testing
- Vitamin treatment (alpha tocopherol plus ascorbic acid)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- NCT04800094
- Testing
- Investigational Liver Fat Quantification Software
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Non Alcoholic Steatohepatitis
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children…
- Trial name
- NCT03883607
- Testing
- Elafibranor 80mg, Elafibranor 120mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genfit
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Non-alcoholic Fatty Liver Disease
A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to demonstrate a reduction of intrahepatic fat as measured with Proton Magnetic Resonance Spectroscopy after 12 weeks administration of oral acarbose.
- Trial name
- NCT00677521
- Testing
- Acarbose
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Non-Alcoholic Fatty Liver Disease
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
The goal of this study is to evaluate the role of probiotics in the treatment of pediatric NAFLD by evaluating for steatosis and fibrosis with a Fibroscan machine.
- Trial name
- NCT04671186
- Testing
- Culturelle (Lactobacillus rhamnosus strain GG)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Northwell Health
Fatty Liver
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
The purpose of this study is to determine if therapeutic modification of insulin resistance or oxidative stress leads to improvement in serum or histologic indicators of liver injury or quality of life.
- Trial name
- TONIC (NCT00063635)
- Testing
- Metformin, Vitamin E
- Where
- 10 sites in United States
- Volunteers
- 173 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Gestational Diabetes
Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy
The aim of this study is to evaluate the prevalence of metabolic syndrome, liver function abnormality and non-alcoholic fatty liver disease in early pregnancy patients, and the risk of pregnancy complications.
- Trial name
- NCT02276144
- Testing
- Liver ultrasound
- Where
- 3 sites in South Korea
- Volunteers
- 2,400 people
- Sponsor
- Seoul National University Hospital
Obesity, Non-Alcoholic Fatty Liver Disease
Evaluation of Intestinal Microbiome in Obese Kids
The goal of this study is to investigate comparisons between the intestinal microbiome in patients with obesity and in patients with obesity and Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT00816296
- Testing
- Blood Draw, Stool collection, BodPod Measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Pediatric Obesity, Metabolic Syndrome
Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound…
- Conditions
- Pediatric Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver, Atherosclerosis
- Trial name
- CardMetSOb (NCT05908877)
- Testing
- History and Clinical evaluation, Biological evaluation of the metabolic syndrome and components, Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage
- Where
- Romania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neoped - Centru de Pediatrie
Nonalcoholic Fatty Liver Disease (NAFLD)
Anti-LPS Antibody Treatment for Pediatric NAFLD
The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver…
- Trial name
- NCT03042767
- Testing
- IMM-124E
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Miriam Vos, MD
NAFLD
NAFLD in Patient of Hypothyroidism
Nonalcoholic fatty liver disease (NAFLD) is the most important chronic liver disease in the western world, affecting almost 30% of the general population.
- Trial name
- NCT05813301
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Antidiabetic Effects on Intrahepatic Fat
This was a 24-week single-center, open-label, parallel controlled group comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease.
- Trial name
- NCT03068065
- Testing
- Liraglutide, Metformin, Gliclazide
- Where
- China
- Volunteers
- 87 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School